Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial

ST. LOUIS, Mo., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that it has completed enrollment of its Phase 3 SOLAR-RECUR clinical trial. The trial is a multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer after radical prostatectomy or radiation therapy. The additional Phase 3 trial, SOLAR-STAGE, a multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in staging of men with newly diagnosed unfavorable intermediate-risk, high-risk or very-high-risk prostate cancer electing to undergo radical prostatectomy with pelvic lymph node dissection continues to enroll patients at sites in the U.S. and will soon open locations in Europe. Read More

Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial

Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial

Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial

Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial

Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial